摘要
目的:将肝癌H22细胞与树突状细胞(DC)相融合,研制杂交瘤苗,并观察瘤苗的生长特性、致瘤性及免疫活性.方法:将DC与肝癌H22细胞融合制备H22-DC融合细胞,磁式分选器分选融合细胞;观察融合细胞的生长特性和体内致瘤性;从Balb/C小鼠皮下接种融合细胞,实验设肿瘤等三组对照,每组各5只小鼠.MTT比色法检测小鼠脾CTL活性.结果:融合细胞在体外能分裂增生,但明显低于肿瘤细胞,无体内致瘤陛;活融合细胞免疫的小鼠,其脾CTL杀伤H22细胞的活性明显高于对照组小鼠(P<0.01).结论:融合细胞能诱导出特异性的CTL活性,可望成为肝癌免疫治疗的新途径.
AIM: To prepare a cancer vaccine (H22-DC) based on fusion of hepatocarcinoma cells (H22) with dendritic cells (DC) of mice and to analyze the biological characteristics, tumori-genicity and specific CTL activity of H22-DC. METHODS: DCs were fused with H22 cells and fusion cells were marked with CD11c MicroBeads. The teachniques of cell culture, immunocytochemistry and light microscopy were used to test the characteristics of growth morphology of H22-DC in vitro. As an immunogen, H22-DC was inoculated subcutaneously into the right armpit of Balb/C mice, and their tumorigenicity in vivo was observed. MTT was used to test the CTL activity of murine spleen in vitro. RESULTS: H22-DC was able to divide and prolifterate in vitro, but its activity of proliferation was significantly decreased as compared with H22 cells and its growth curve was flatter than that of H22 cells. The spleen CTL activity against H22 cells in mice implanted with fresh H22-DC was significantly higher than that in control groups (P <0.01). CONCLUSION: H22-DC can significantly stimulate the specific CTL activity of murine spleen. The DC vaccine is likely to become a helpful approach in immunotherapy of hepa-tocellular carcinoma.
出处
《世界华人消化杂志》
CAS
2004年第2期276-279,共4页
World Chinese Journal of Digestology
基金
广东省自然科学基金资助项目
No.980180~~
